Global Multiple Myeloma Treatment Market Research Report: By Treatment (Chemotherapy, Radiation Therapy, Stem Cell Transplant, Corticosteroids, Interferon, and Others), End User (Hospitals, Clinics, Independent Pharmacies, and Others)—Forecast till 2027
ID: MRFR/Pharma/5354-HCR | February 2021 | Region: Global | 90 pages
Market Scenario:
The global multiple myeloma treatment market is expected to rise steadily at a CAGR of 11.0% during the forecast period from 2018–2023.
Multiple myeloma is a cancer of plasma cells. Plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells which includes T cells and B cells that work together to fight against infections and other diseases. Lymphocytes are one of the important types of white blood cells (WBCs) in the immune system. Different types of lymphocytes are present in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream.
The global multiple myeloma market is anticipated to grow by an increase in aging population, increase in healthcare expenditure, and increasing use of novel cancer drugs in the market, whereas increasing prevalence of disease along with growing elderly population is the prime factor to drive the growth of this market during the forecast period. It has also been observed that the upcoming drug pipeline of multiple myeloma is promising. Other factors such as biological drugs and stem cell therapies are expected to drive the market in the future. The key players in the market are accelerating the research and development activities for multiple myeloma treatment. In 2018, drugs therapy is expected to be the largest market due to key driving factors such as rising demand for non-invasive treatments, and incessant development in research and development activities.
Despite the drivers, factors such as the high cost of treatment and limited target patient population may hinder the growth of the market.
Key players:
Some of the key players in the global multiple myeloma treatment market are Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Genzyme Corporation, Juno Therapeutics, Johnson & Johnson, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Innate Pharma SA, and Celldex Therapeutics, Inc., Onyx Pharmaceuticals, Pfizer, Takeda Pharmaceuticals.
Intended Audience
- Manufacturers and Suppliers
- Hospitals and clinics
- Laboratories and Associations
- Research institutes
Market Segmentation:
Global multiple myeloma treatment is further segmented into treatment types and end-users. Based on treatment types the market is segmented into chemotherapy, corticosteroids, interferon, stem cell transplant, and radiation therapy. Chemotherapy is further sub-segmented into bendamustine (treanda), cyclophosphamide (Cytoxan), doxorubicin (adriamycin), etoposide (vp-16), liposomal doxorubicin (Doxil), melphalan (Alkeran, evomela), vincristine (Oncovin). On the basis of end-user global multiple myeloma treatment market is further segmented into hospitals, clinics, rehabilitative center treatment, independent pharmacies, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The multiple myeloma treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of multiple myeloma treatment market.
The European multiple myeloma treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The multiple myeloma treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The multiple myeloma treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, North America is expected to hold the largest share in global multiple myeloma treatment market due to key driving factors such as rising prevalence of multiple myeloma, high awareness associated with early cancer diagnosis and treatment, supportive reimbursement policies, and developed healthcare infrastructure.
Europe has been dominating the multiple myeloma treatment market owing to the faster approval rates and favorable healthcare policies and the presence of major players in this region. Higher prevalence of multiple myeloma in developed economies is driving the growth of the Europe market.
Asia-Pacific is expected to show exponential growth due to rising awareness associated with cancer diagnosis and developing healthcare infrastructure is responsible for high accessibility to modern technology.
Furthermore, factors such as increased healthcare infrastructure and improved healthcare reimbursement policies are responsible for the growth of multiple myeloma treatment market in the Middle East and Africa.
Global Multiple Myeloma Treatment Market Share (%), by Region, 2017
Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American Association of the neurological surgeon
Segmentation
Global Multiple Myeloma Treatment Market, by Treatment
- Chemotherapy
- Bendamustine (Treanda)
- Cyclophosphamide (Cytoxan)
- Doxorubicin (Adriamycin)
- Etoposide
- Liposomal doxorubicin (Doxil)
- Melphalan (Alkeran, Evomela)
- Vincristine (Oncovin)
- Corticosteroids
- Interferon
- Stem Cell Transplant
- Radiation Therapy
Global Multiple Myeloma Treatment Market, by End User
- Hospitals
- Clinics
- Independent pharmacies
- Others
Global Multiple Myeloma Treatment Market, by Region
- Americas
- North America
- US
- Canada
- South America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Republic of Korea
- Rest of Asia Pacific
- Middle East & Africa
- Middle East
- Africa
Frequently Asked Questions (FAQ) :
The multiple myeloma treatment market is projected to grow at an 11.0% CAGR between 2020-2027.
North America is projected to command the largest share in the multiple myeloma treatment market.
Rise in healthcare expenditure and growing elderly population is boosting market growth.
High treatment cost may limit the multiple myeloma treatment market growth.
Different end use industries of the multiple myeloma treatment market include independent pharmacies, hospitals, clinics, and others.
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Multiple Myeloma Treatment Market, by Treatment
6.1 Introduction
6.2 Chemotherapy
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.1 Bendamustine (Treanda)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.2 Cyclophosphamide (Cytoxan)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.3 Doxorubicin (Adriamycin)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.4 Etoposide
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.5 Liposomal doxorubicin (Doxil)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.6 Melphalan (Alkeran, Evomela)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.7 Vincristine (Oncovin)
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3 Corticosteroids
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.4 Interferon
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.5 Stem Cell Transplant
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.6 Radiation therapy
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
Chapter 7. Global Multiple Myeloma Treatment Market, by End-User
7.1 Introduction
7.2 Hospitals
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.3 Clinics
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.4 Independent Pharmacies
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.5 Other
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
Chapter 8. Global Multiple Myeloma Treatment Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 UK
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia-Pacific
8.5 Middle East & Africa
8.5.1 Middle East
8.5.2 Africa
Chapter 9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
Chapter 10. Company Profiles
10.1 Celgene Corporation
10.1.1 Company Overview
10.1.2 Product Overview
10.1.3 Financials Overview
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Janssen Biotech, Inc.
10.2.1 Company Overview
10.2.2 Product Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Bristol-Myers Squibb Company
10.3.1 Company Overview
10.3.2 Product Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Product Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Millennium Pharmaceuticals
10.5.1 Company Overview
10.5.2 Product Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Amgen, Inc
10.6.1 Company Overview
10.6.2 Product Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Genzyme Corporation
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financial Overview
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Juno Therapeutics
10.8.1 Overview
10.8.2 Product Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.7 Johnson & Johnson
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 F. Hoffmann-La Roche Ltd
10.8.1 Overview
10.8.2 Product Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.11 GlaxoSmithKline plc
10.91 Overview
10.92 Product Overview
10.93 Financials
10.94 Key Developments
10.95 SWOT Analysis
10.10 AbbVie Inc
10.10.1 Overview
10.10.2 Product Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.13 Innate Pharma SA
10.13.1 Overview
10.13.2 Product Overview
10.13.3 Financials
10.13.4 Key Developments
10.13.5 SWOT Analysis
10.14 Celldex Therapeutics, Inc
10.14.1 Overview
10.14.2 Product Overview
10.14.3 Financials
10.14.4 Key Developments
10.14.5 SWOT Analysis
10.15 Onyx Pharmaceuticals
10.15.1 Overview
10.15.2 Product Overview
10.15.3 Financials
10.15.4 Key Developments
10.15.5 SWOT Analysis
10.16 Pfizer
10.16.1 Overview
10.16.2 Product Overview
10.16.3 Financials
10.16.4 Key Developments
10.16.5 SWOT Analysis
10.17 Takeda Pharmaceuticals
10.17.1 Overview
10.17.2 Product Overview
10.17.3 Financials
10.17.4 Key Developments
10.17.5 SWOT Analysis
Chapter 11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s Viewpoint
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Predictions for the Multiple Myeloma Treatment Market
Chapter 12. Appendix
LIST OF TABLES
Table 1 Global Multiple Myeloma Treatment Market Synopsis, 2020–2027
Table 2 Global Multiple Myeloma Treatment Market Estimates and Forecast, 2020–2027 (USD Million)
Table 3 Global Multiple Myeloma Treatment Market, by Region, 2020–2027 (USD Million)
Table 4 Global Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 5 Global Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 6 North America: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 7 North America: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 8 US: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 9 US: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 10 Canada: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 11 Canada: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 12 South America: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 13 South America: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 14 Europe: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 15 Europe: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 16 Western Europe: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 17 Western Europe: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 18 Eastern Europe: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 19 Eastern Europe: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 20 Asia-Pacific: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)
Table 21 Asia-Pacific: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
Table 22 Middle East & Africa: Multiple Myeloma Treatment Market, by Treatment, 2020-2027 (USD Million)
Table 23 Middle East & Africa: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Multiple Myeloma Treatment Market
Figure 3 Segmentation Market Dynamics for Global Multiple Myeloma Treatment Market
Figure 4 Global Multiple Myeloma Treatment Market Share, by Treatment, 2020
Figure 5 Global Multiple Myeloma Treatment Market Share, by End-User, 2020
Figure 6 Global Multiple Myeloma Treatment Market Share, by Region, 2020
Figure 7 North America: Multiple Myeloma Treatment Market Share, by Country, 2020
Figure 8 Europe: Multiple Myeloma Treatment Market Share, by Country, 2020
Figure 9 Asia-Pacific: Multiple Myeloma Treatment Market Share, by Country, 2020
Figure 10 Middle East & Africa: Multiple Myeloma Treatment Market Share, by Country, 2020
Figure 11 Global Multiple Myeloma Treatment Market: Company Share Analysis, 2020 (%)
Figure 12 Celgene Corporation: Key Financials
Figure 13 Celgene Corporation: Segmental Revenue
Figure 14 Celgene Corporation: Geographical Revenue
Figure 15 Janssen Biotech, Inc.: Key Financials
Figure 16 Janssen Biotech, Inc.: Segmental Revenue
Figure 17 Janssen Biotech, Inc.: Geographical Revenue
Figure 18 Bristol-Myers Squibb Company: Key Financials
Figure 19 Bristol-Myers Squibb Company: Segmental Revenue
Figure 20 Bristol-Myers Squibb Company: Geographical Revenue
Figure 21 Novartis AG: Key Financials
Figure 22 Novartis AG: Segmental Revenue
Figure 23 Novartis AG: Geographical Revenue
Figure 24 Millennium Pharmaceuticals: Key Financials
Figure 25 Millennium Pharmaceuticals: Segmental Revenue
Figure 26 Millennium Pharmaceuticals. Geographical Revenue
Figure 27 Amgen, Inc: Key Financials
Figure 28 Amgen, Inc: Segmental Revenue
Figure 29 Amgen, Inc: Geographical Revenue
Figure 30 Genzyme Corporation: Key Financials
Figure 31 Genzyme Corporation: Segmental Revenue
Figure 32 Genzyme Corporation: Geographical Revenue
Figure 33 Juno Therapeutics: Key Financials
Figure 34 Juno Therapeutics: Segmental Revenue
Figure 35 Juno Therapeutics: Geographical Revenue
Figure 36 Johnson & Johnson: Key Financials
Figure 37 Johnson & Johnson: Segmental Revenue
Figure 38 Johnson & Johnson: Geographical Revenue
Figure 39 F. Hoffmann-La Roche Ltd: Key Financials
Figure 40 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 41 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 42 GlaxoSmithKline plc: Key Financials
Figure 43 GlaxoSmithKline plc: Segmental Revenue
Figure 44 GlaxoSmithKline plc: Geographical Revenue
Figure 45 AbbVie Inc: Key Financials
Figure 46 AbbVie Inc: Segmental Revenue
Figure 47 AbbVie Inc: Geographical Revenue
Figure 48 Innate Pharma SA: Key Financials
Figure 49 Innate Pharma SA: Segmental Revenue
Figure 50 Innate Pharma SA: Geographical Revenue
Figure 51 Celldex Therapeutics, Inc: Key Financials
Figure 52 Celldex Therapeutics, Inc: Segmental Revenue
Figure 53 Celldex Therapeutics, Inc: Geographical Revenue
Figure 54 BrainScope Company, Inc, Inc: Key Financials
Figure 55 BrainScope Company, Inc, Inc: Segmental Revenue
Figure 56 BrainScope Company, Inc, Inc: Geographical Revenue
Figure 57 Pfizer, Inc: Key Financials
Figure 58 Pfizer, Inc: Segmental Revenue
Figure 59 Pfizer, Inc: Geographical Revenue
Figure 60 Takeda Pharmaceuticals, Inc: Key Financials
Figure 61 Takeda Pharmaceuticals, Inc: Segmental Revenue
Figure 62 Takeda Pharmaceuticals, Inc: Geographical Revenue
Figure 63 Onyx Pharmaceuticals: Key Financials
Figure 64 Onyx Pharmaceuticals: Segmental Revenue
Figure 65 Onyx Pharmaceuticals: Geographical Revenue
Figure 66 Silver Creek Pharmaceuticals Inc: Key Financials
Figure 67 Silver Creek Pharmaceuticals Inc: Segmental Revenue
Figure 68 Silver Creek Pharmaceuticals Inc: Geographical Revenue
Figure 69 Stemedica Cell Technologies Inc: Key Financials
Figure 70 Stemedica Cell Technologies Inc: Segmental Revenue
Figure 71 Stemedica Cell Technologies Inc: Geographical Revenue
Figure 72 Banayan Biomarkers Inc: Key Financials
Figure 73 Banayan Biomarkers Inc: Segmental Revenue
Figure 74 Banayan Biomarkers Inc: Geographical Revenue
Figure 75 Vasopharm GmbH: Key Financials
Figure 76 Vasopharm GmbH: Segmental Revenue
Figure 77 Vasopharm GmbH: Geographical Revenue